StockData
Evotec SE logo

Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.48−0.08 (-5.13%)

Close on Nov 17, 2026Market cap $526.23MP/E –Yield –

Evotec operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -€56.22M. The highest annual figure on record is €62.71M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€56.22M–
FY2024Dec 31, 2024-€142.52M–
FY2023Dec 31, 2023-€47.51M-327.9%
FY2022Dec 31, 2022€20.85M-49.1%
FY2021Dec 31, 2021€41.00M-15.6%
FY2020Dec 31, 2020€48.56M-22.6%
FY2019Dec 31, 2019€62.71M–

More Evotec figures

See a number that looks wrong?